Retatrutide Side Effects: What Studies Show
Last updated 13 June 2026
Quick answer
What trials reported
Across the studies, the main reports were in the gut. People most often mentioned:
- Nausea (feeling sick)
- Diarrhoea
- Being sick (vomiting)
- Constipation
- Less appetite
How bad were they?
Most were mild or moderate. They showed up more when the dose was raised fast. Slower dose steps lined up with fewer problems in the data. This is one reason trials build the dose up slowly — see dosing in studies.
Why stomach effects happen
The same gut signals that lower appetite also slow the stomach down. That is helpful for weight research, but it can also cause nausea, especially early on. As the body gets used to it, these effects often ease.
The honest limits of what we know
Retatrutide is still in trials. Short and medium studies give a good early picture, but the full long-term safety in people will only be clear once the large Phase 3 trials finish and are reviewed. For the trial background, see our clinical trials page.
Important
Retatrutide is not an approved medicine in the UK. This page sums up trial findings. It is not a guide for taking anything. See our medical disclaimer.
Knowing the side-effect picture matters before you buy retatrutide UK for any research use.
Looking at suppliers?
What a trustworthy UK supplier looks likeCommon questions
What is the most common side effect?+
In trials, the most common reports were stomach-related: nausea, diarrhoea, and being sick. Most were mild to moderate and often eased over time.
Is retatrutide safe?+
It is still being tested. Trials so far report a side-effect pattern similar to other GLP-1 peptides. Long-term safety in people is not yet settled because the research is ongoing, and it is not an approved medicine.
Do side effects get better over time?+
In trials, stomach side effects were most common early and when the dose went up. They often settled as the body adjusted. A slower dose build lined up with fewer problems.
Are there serious side effects?+
Most reports in trials were mild to moderate. As with any drug in testing, rare or serious effects can only be fully known once large, long trials finish.